Tech Company Financing Transactions
Clade Therapeutics Funding Round
Clade Therapeutics, based in Cambridge, received $87 million from Syncona, Bristol-Myers Squibb and Emerson Collective.
Transaction Overview
Company Name
Announced On
11/6/2021
Transaction Type
Venture Equity
Amount
$87,000,000
Round
Series A
Investors
Syncona (Lead Investor) (Martin Murphy)
Emerson Collective (Neil White)
LifeSci Venture Partners (Ryan Cinalli)
Proceeds Purpose
Proceeds from this financing will support the development of the Company's proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Our platform technology immune cloaks human pluripotent stem cells and their adult derivatives enabling the development of true 'off-the-shelf' cell transplantation therapies. Combined with an unparalleled expertise in generating stem cell-derived adult T, NK and B cells, Clade promises to become a leading innovator in developing widely accessible cell medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chad Cowan
Chief Operating Officer
Leandro Vetcher
President
James Glasheen
Browse more venture capital transactions:
Prev: 11/6/2021: Parthenon Therapeutics venture capital transaction
Next: 11/6/2021: Thirteen Lune venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs